Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Sep 15;100(6):1634–1639. doi: 10.1172/JCI119687

Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor.

P Kopp 1, S Muirhead 1, N Jourdain 1, W X Gu 1, J L Jameson 1, C Rodd 1
PMCID: PMC508345  PMID: 9294132

Abstract

Activating somatic mutations in the thyrotropin (TSH) receptor have been identified as a cause of hyperfunctioning thyroid adenomas, and germline mutations have been found in familial nonautoimmune hyperthyroidism and sporadic congenital hyperthyroidism. All mutations reported to date have been located in the transmembrane domain. We now report an example of an activating mutation in the extracellular, TSH-binding domain, found in a male infant with congenital hyperthyroidism due to a toxic adenoma. The pregnancy was remarkable for fetal tachycardia. Scintigraphic studies demonstrated a large nodule in the right lobe, and a hemithyroidectomy was performed at the age of 2 yr. Direct sequencing of the TSH receptor gene revealed a mutation in one allele resulting in a substitution of serine281 by isoleucine (Ser281--> Ile) in the extracellular domain. The mutation was restricted to the adenomatous tissue. Expression of the Ser281--> Ile mutation in vitro revealed an increase in basal cAMP levels. Affinity for TSH was increased by the mutation. These findings demonstrate that activating mutations can also occur in the extracellular domain of the TSH receptor, and support a model in which the extracellular domain serves to restrain receptor function in the absence of TSH or antibody-induced conformational changes.

Full Text

The Full Text of this article is available as a PDF (311.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berridge M. J., Dawson R. M., Downes C. P., Heslop J. P., Irvine R. F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J. 1983 May 15;212(2):473–482. doi: 10.1042/bj2120473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution. J Clin Endocrinol Metab. 1996 Aug;81(8):2783–2785. doi: 10.1210/jcem.81.8.8768829. [DOI] [PubMed] [Google Scholar]
  3. Duprez L., Parma J., Van Sande J., Allgeier A., Leclère J., Schvartz C., Delisle M. J., Decoulx M., Orgiazzi J., Dumont J. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet. 1994 Jul;7(3):396–401. doi: 10.1038/ng0794-396. [DOI] [PubMed] [Google Scholar]
  4. Fort P., Lifshitz F., Pugliese M., Klein I. Neonatal thyroid disease: differential expression in three successive offspring. J Clin Endocrinol Metab. 1988 Mar;66(3):645–647. doi: 10.1210/jcem-66-3-645. [DOI] [PubMed] [Google Scholar]
  5. Fradkin J. E., Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore) 1983 Jan;62(1):1–20. doi: 10.1097/00005792-198301000-00001. [DOI] [PubMed] [Google Scholar]
  6. Granoff A. B., Hershman J. M. Suppression of pituitary TSH in a child with a hyperfunctioning thyroid nodule. J Pediatr. 1977 Jan;90(1):83–85. doi: 10.1016/s0022-3476(77)80771-3. [DOI] [PubMed] [Google Scholar]
  7. Gu W. X., Du G. G., Kopp P., Rentoumis A., Albanese C., Kohn L. D., Madison L. D., Jameson J. L. The thyrotropin (TSH) receptor transmembrane domain mutation (Pro556-Leu) in the hypothyroid hyt/hyt mouse results in plasma membrane targeting but defective TSH binding. Endocrinology. 1995 Jul;136(7):3146–3153. doi: 10.1210/endo.136.7.7789342. [DOI] [PubMed] [Google Scholar]
  8. Hirayu H., Magnusson R. P., Rapoport B. Studies on the mechanism of desensitization of the cyclic AMP response to TSH stimulation in a cloned rat thyroid cell line. Mol Cell Endocrinol. 1985 Aug;42(1):21–27. doi: 10.1016/0303-7207(85)90003-6. [DOI] [PubMed] [Google Scholar]
  9. Kopp P., Kimura E. T., Aeschimann S., Oestreicher M., Tobler A., Fey M. F., Studer H. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab. 1994 Jul;79(1):134–139. doi: 10.1210/jcem.79.1.7517946. [DOI] [PubMed] [Google Scholar]
  10. Kopp P., van Sande J., Parma J., Duprez L., Gerber H., Joss E., Jameson J. L., Dumont J. E., Vassart G. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med. 1995 Jan 19;332(3):150–154. doi: 10.1056/NEJM199501193320304. [DOI] [PubMed] [Google Scholar]
  11. Kosugi S., Ban T., Kohn L. D. Identification of thyroid-stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor. Mol Endocrinol. 1993 Jan;7(1):114–130. doi: 10.1210/mend.7.1.8095322. [DOI] [PubMed] [Google Scholar]
  12. Lefkowitz R. J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci. 1993 Aug;14(8):303–307. doi: 10.1016/0165-6147(93)90048-O. [DOI] [PubMed] [Google Scholar]
  13. Lyons J., Landis C. A., Harsh G., Vallar L., Grünewald K., Feichtinger H., Duh Q. Y., Clark O. H., Kawasaki E., Bourne H. R. Two G protein oncogenes in human endocrine tumors. Science. 1990 Aug 10;249(4969):655–659. doi: 10.1126/science.2116665. [DOI] [PubMed] [Google Scholar]
  14. Namba H., Matsuo K., Fagin J. A. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990 Jul;86(1):120–125. doi: 10.1172/JCI114673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Namba H., Ross J. L., Goodman D., Fagin J. A. Solitary polyclonal autonomous thyroid nodule: a rare cause of childhood hyperthyroidism. J Clin Endocrinol Metab. 1991 May;72(5):1108–1112. doi: 10.1210/jcem-72-5-1108. [DOI] [PubMed] [Google Scholar]
  16. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 1993 Oct 14;365(6447):649–651. doi: 10.1038/365649a0. [DOI] [PubMed] [Google Scholar]
  17. Parma J., Van Sande J., Swillens S., Tonacchera M., Dumont J., Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Mol Endocrinol. 1995 Jun;9(6):725–733. doi: 10.1210/mend.9.6.8592518. [DOI] [PubMed] [Google Scholar]
  18. Paschke R., Tonacchera M., Van Sande J., Parma J., Vassart G. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab. 1994 Dec;79(6):1785–1789. doi: 10.1210/jcem.79.6.7989485. [DOI] [PubMed] [Google Scholar]
  19. Popma B. H., Cloutier M. D., Hayles A. B. Thyroid nodule producing T3 toxicosis in a child. Mayo Clin Proc. 1973 Apr;48(4):273–275. [PubMed] [Google Scholar]
  20. Porcellini A., Ciullo I., Laviola L., Amabile G., Fenzi G., Avvedimento V. E. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab. 1994 Aug;79(2):657–661. doi: 10.1210/jcem.79.2.8045989. [DOI] [PubMed] [Google Scholar]
  21. Russo D., Arturi F., Suarez H. G., Schlumberger M., Du Villard J. A., Crocetti U., Filetti S. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 1996 Apr;81(4):1548–1551. doi: 10.1210/jcem.81.4.8636365. [DOI] [PubMed] [Google Scholar]
  22. Russo D., Arturi F., Wicker R., Chazenbalk G. D., Schlumberger M., DuVillard J. A., Caillou B., Monier R., Rapoport B., Filetti S. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 1995 Apr;80(4):1347–1351. doi: 10.1210/jcem.80.4.7714109. [DOI] [PubMed] [Google Scholar]
  23. Shenker A. G protein-coupled receptor structure and function: the impact of disease-causing mutations. Baillieres Clin Endocrinol Metab. 1995 Jul;9(3):427–451. doi: 10.1016/s0950-351x(95)80519-2. [DOI] [PubMed] [Google Scholar]
  24. Spiegel A. M. Mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab. 1996 Jul;81(7):2434–2442. doi: 10.1210/jcem.81.7.8675557. [DOI] [PubMed] [Google Scholar]
  25. Takeshita A., Nagayama Y., Yokoyama N., Ishikawa N., Ito K., Yamashita T., Obara T., Murakami Y., Kuma K., Takamatsu J. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin Endocrinol Metab. 1995 Sep;80(9):2607–2611. doi: 10.1210/jcem.80.9.7673402. [DOI] [PubMed] [Google Scholar]
  26. Tonacchera M., Cetani F., Parma J., Van Sande J., Vassart G., Dumont J. Oncogenic mutations in thyroid adenoma: methodological criteria. Eur J Endocrinol. 1996 Oct;135(4):444–446. doi: 10.1530/eje.0.1350444. [DOI] [PubMed] [Google Scholar]
  27. Tonacchera M., Van Sande J., Cetani F., Swillens S., Schvartz C., Winiszewski P., Portmann L., Dumont J. E., Vassart G., Parma J. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab. 1996 Feb;81(2):547–554. doi: 10.1210/jcem.81.2.8636266. [DOI] [PubMed] [Google Scholar]
  28. Van Sande J., Massart C., Costagliola S., Allgeier A., Cetani F., Vassart G., Dumont J. E. Specific activation of the thyrotropin receptor by trypsin. Mol Cell Endocrinol. 1996 May 31;119(2):161–168. doi: 10.1016/0303-7207(96)03804-x. [DOI] [PubMed] [Google Scholar]
  29. Van Sande J., Parma J., Tonacchera M., Swillens S., Dumont J., Vassart G. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab. 1995 Sep;80(9):2577–2585. doi: 10.1210/jcem.80.9.7673398. [DOI] [PubMed] [Google Scholar]
  30. Vassart G., Dumont J. E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev. 1992 Aug;13(3):596–611. doi: 10.1210/edrv-13-3-596. [DOI] [PubMed] [Google Scholar]
  31. Zakarija M., McKenzie J. M., Hoffman W. H. Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism. J Clin Endocrinol Metab. 1986 Feb;62(2):368–371. doi: 10.1210/jcem-62-2-368. [DOI] [PubMed] [Google Scholar]
  32. Zakarija M., McKenzie J. M. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab. 1983 Nov;57(5):1036–1040. doi: 10.1210/jcem-57-5-1036. [DOI] [PubMed] [Google Scholar]
  33. Zhang M. L., Sugawa H., Kosugi S., Mori T. Constitutive activation of the thyrotropin receptor by deletion of a portion of the extracellular domain. Biochem Biophys Res Commun. 1995 Jun 6;211(1):205–210. doi: 10.1006/bbrc.1995.1797. [DOI] [PubMed] [Google Scholar]
  34. de Roux N., Misrahi M., Chatelain N., Gross B., Milgrom E. Microsatellites and PCR primers for genetic studies and genomic sequencing of the human TSH receptor gene. Mol Cell Endocrinol. 1996 Mar 25;117(2):253–256. doi: 10.1016/0303-7207(95)03753-5. [DOI] [PubMed] [Google Scholar]
  35. de Roux N., Polak M., Couet J., Leger J., Czernichow P., Milgrom E., Misrahi M. A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab. 1996 Jun;81(6):2023–2026. doi: 10.1210/jcem.81.6.8964822. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES